Search
Please see below for a list of search results.
This document sets out the strategy for the Human Tissue Authority (HTA). It describes our strategic approach and direction, key challenges and opportunities, our strategic objectives and how we will deploy our resources on the priority areas identified over the next three...
During 2017, the HTA undertook a fundamental review of its strategy. This exercise gave us considerable reassurance that the public and professionals think we are on the right track with our regulatory approach.
The HTA’s high-level aims, objectives and key milestones and deliverables for 2018/19 are set out in this section. This information is supported by our key performance indicators (KPIs) and performance indicators (PIs), which set out how we will measure whether we are achieving those aims.
Our strategic approach is based on right-touch regulation. This means being clear on the risks we are regulating, being proportionate and targeted in regulating those risks, taking into account the role of professional bodies and other regulators, and using the minimum necessary regulatory force...
In preparing this strategy, the HTA has undertaken a fundamental evaluation of the extent to which our current strategic approach protects public and professional confidence in the proper use, and quality and safety of, human tissues, cells and organs.
The law on cryonics: who makes the decision, is there an age limit, are there plans to change the law and what happens to my body if the organisation goes bankrupt?
The law on cryonics: who makes the decision, is there an age limit, are there plans to change the law and what happens to my body if the organisation goes bankrupt?